For two patients with MTC and liver, bone, and lung metastases along with elevated Ctn (>2000 ng/L), comprehensive treatment, including high-selectivity RET inhibitors, such as pralsetinib or selpercatinib, is recommended [4,16,17]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.